Amylyx Pharmaceuticals Inc.
Organization details
- Legal name
- Amylyx Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AMLX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001658551
- EIN
- 46-4600503
Board of directors
-
Bernhardt G. Zeiher · DirectorSince 2024
-
Daphne Quimi · DirectorSince 2023
-
George M. Milne Jr. · DirectorSince 2023
-
Joshua B. Cohen · Director · Co-Chief Executive OfficerSince 2023
-
Justin B. Klee · Director · Co-Chief Executive OfficerSince 2023
-
Karen Firestone · DirectorSince 2023
-
Paul R. Fonteyne · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.5%
-
94.8%
Board connections
5 of this board's directors also sit on 6 other boards. 5 are in the same sector.
-
Abeona Therapeutics Inc. Same sectorvia Bernhardt G. Zeiher
-
Apnimed Inc. Same sectorvia Paul R. Fonteyne
-
Aurinia Pharmaceuticals Inc Same sectorvia George M. Milne Jr.
-
Century Therapeutics Inc. Same sectorvia Daphne Quimi
-
Entrada Therapeutics Inc. Same sectorvia Bernhardt G. Zeiher
- via Joshua B. Cohen
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $152,183
- 2 purchases by 1 insider
- Sold, last 12 months
- $10,135,197
- 31 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | George M. Milne Jr. Director | Open-market sale | −30,000 | $27.70 | $830,904 |
| Sep 10, 2026 | Justin B. Klee Director, Officer (Co-Chief Executive Officer) | Open-market sale | −29,025 | $32.13 | $932,573 |
| Sep 10, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Open-market sale | −29,545 | $32.16 | $950,167 |
| Sep 10, 2026 | Mazzariello Gina Officer (Chief Legal Officer) | Open-market sale | −9,525 | $32.46 | $309,182 |
| Sep 10, 2026 | FRATES JAMES M Officer (Chief Financial Officer) | Open-market sale | −9,768 | $32.27 | $315,213 |
| Sep 10, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Open-market sale | −7,947 | $32.21 | $255,973 |
| Sep 10, 2026 | Justin B. Klee Director, Officer (Co-Chief Executive Officer) | Open-market sale | −1,439 | $33.16 | $47,717 |
| Sep 10, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Open-market sale | −919 | $33.15 | $30,465 |
| Sep 10, 2026 | Mazzariello Gina Officer (Chief Legal Officer) | Open-market sale | −11 | $33.34 | $367 |
| Sep 10, 2026 | FRATES JAMES M Officer (Chief Financial Officer) | Open-market sale | −1,042 | $33.23 | $34,626 |
| Sep 10, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Open-market sale | −2,081 | $33.09 | $68,860 |
| Aug 31, 2026 | Karen Firestone Director | Option exercise | +25,000 | $1.76 | $44,000 |
| Aug 31, 2026 | Karen Firestone Director | Option exercise | +25,000 | $5.05 | $126,250 |
| Aug 18, 2026 | Joshua B. Cohen Director, Officer (Co-Chief Executive Officer) | Grant or award | +60,039 | — | — |
| Aug 18, 2026 | Camille L. Bedrosian Officer (Chief Medical Officer) | Grant or award | +22,807 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Amylyx Pharmaceuticals Inc.
Who is the CEO of Amylyx Pharmaceuticals Inc.?
Justin B. Klee is Amylyx Pharmaceuticals Inc.'s Co-Chief Executive Officer.
How many directors are on Amylyx Pharmaceuticals Inc.'s board?
Amylyx Pharmaceuticals Inc.'s board has 7 directors: Bernhardt G. Zeiher, Daphne Quimi, George M. Milne Jr., Joshua B. Cohen, Justin B. Klee, Karen Firestone and Paul R. Fonteyne.
Are Amylyx Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Amylyx Pharmaceuticals Inc. insiders bought $152,183 of shares in 2 purchases and sold $10.1 million of shares in 31 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="amylyx-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.